These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9256134)

  • 21. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
    Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A
    Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer.
    Vokes EE; Gordon GS; Rudin CM; Mauer AM; Watson S; Krauss S; Arrieta R; Golomb HM; Hoffman PC
    Invest New Drugs; 2001; 19(4):329-33. PubMed ID: 11561694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
    BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas.
    Wilson WH; Little R; Pearson D; Jaffe ES; Steinberg SM; Cheson BD; Humphrey R; Kohler DR; Elwood P
    J Clin Oncol; 1998 Jul; 16(7):2345-51. PubMed ID: 9667249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
    Ferrari V; Valcamonico F; Amoroso V; Simoncini E; Vassalli L; Marpicati P; Rangoni G; Grisanti S; Pasinetti N; Marini G
    Oncology; 2005; 69(4):283-9. PubMed ID: 16282707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
    Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
    Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
    Royce ME; McGarry W; Bready B; Dakhil SR; Belt RJ; Goodwin JW; Gray R; Hoff PM; Winn R; Pazdur R
    J Clin Oncol; 1999 Oct; 17(10):3276-82. PubMed ID: 10506630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outpatient therapy with irinotecan and low-dose cisplatin for metastatic colorectal cancer resistant to 5-fluorouracil.
    Shimada S; Yagi Y; Shiomori K; Kuramoto M; Aoki N; Ogawa M
    Oncol Rep; 2002; 9(4):783-7. PubMed ID: 12066209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
    Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
    J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer.
    Hoff PM; Wolff RA; Xiong H; Jones D; Lin E; Eng C; Dutta A; Bogaard KR; Abbruzzese JL
    Cancer; 2006 May; 106(10):2241-6. PubMed ID: 16598762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
    Herben VM; Schellens JH; Swart M; Gruia G; Vernillet L; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1897-905. PubMed ID: 10561231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.
    Sadahiro S; Suzuki T; Maeda Y; Tanaka A; Ishikawa K; Makuuchi H; Murayama C
    Oncology; 2009; 76(5):338-41. PubMed ID: 19307740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
    Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
    Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
    Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
    J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I trial of CPT-11 in combination with 5-fluorouracil plus leucovorin chemotherapy for patients with metastatic colorectal cancer.
    Yamaguchi Y; Minami K; Kawabuchi Y; Emi M
    Hepatogastroenterology; 2006; 53(68):201-5. PubMed ID: 16608024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of 9-aminocamptothecin in patients with refractory breast cancer.
    Kraut EH; Balcerzak SP; Young D; O'Rourke MA; Petrus JJ; Kuebler JP; Mayernik DG
    Cancer Invest; 2000; 18(1):28-31. PubMed ID: 10701364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer.
    Chiara S; Nobile MT; Tomasello L; Acquati M; Taveggia P; Murolo C; Percivale P; Rosso R
    Anticancer Res; 2005; 25(2B):1391-6. PubMed ID: 15865096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
    Creemers GJ; Gerrits CJ; Schellens JH; Planting AS; van der Burg ME; van Beurden VM; de Boer-Dennert M; Harteveld M; Loos W; Hudson I; Stoter G; Verweij J
    J Clin Oncol; 1996 Sep; 14(9):2540-5. PubMed ID: 8823333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.